Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older: HP40-160/2016E-PDF
"The objective of this Statement Update is to provide evidence and interim recommendations for the use of PNEU-C-13 in immunocompetent adults over 65 years of age and to allow informed decision making in cases when PNEU-C-13 is being considered on an individual basis for use in this age group. This statement: updates the epidemiology of pneumococcal disease in Canada for strains prevented by PNEU-C-13 to the year of the most recently available data (2013); provides an update to the review of the literature on the use of PNEU-C-13 in immunocompetent adults, which includes the recently published CAPiTA trial, as well as randomised controlled trials (RCTs) that investigate safety and immunogenicity; and provides updated, interim, recommendations for the use of PNEU-C-13 in immunocompetent individuals who are 65 years of age and over“--Introduction, p. 5.
|Department/Agency||Public Health Agency of Canada. National Advisory Committee on Immunization.|
|Title||Update on the use of 13-valent pneumococcal conjugate vaccine (PNEU-C-13) in addition to 23-valent pneumococcal polysaccharide vaccine (PNEU-P-23) in immunocompetent adults 65 years of age and older|
|Other Language Editions||[French]|
|Electronic Document|| |
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact the authoring department to request a format other than those available.
We invite you to consult the Frequently Asked Questions page for additional information regarding the Archived Content notice.
Note: The URLs contained in this/these document(s) may no longer be functional
|Note||Issued also in French under title: Mise à jour sur l’utilisation du vaccin conjugué 13-valent (Pneu-C-13) en plus du vaccin polysaccharidique 23-valent contre le pneumocoque (Pneu-P-23) chez les adultes immunocompétents âgés de 65 ans et plus : recommandation provisoire.|
|Number of Pages||27 p.|
|Departmental Catalogue Number||160085|
|Subject Terms||Influenza, Immunization, Seniors|
- Date modified: